353 words
Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter
AVR Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) continued to advance its pivotal PARADIGM Trial and expand manufacturing capacity in the third quarter of 2026 as it prepares to commercialise the DurAVR transcatheter heart valve system. The global healthcare company…